Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $0 | $2 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | 0.7% | – |
| R&D Expenses | $1 | $1 | $2 | $1 |
| G&A Expenses | $1 | $1 | $2 | $2 |
| SG&A Expenses | $1 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $5 | $4 |
| Operating Income | -$2 | -$2 | -$5 | -$4 |
| % Margin | – | – | -225% | – |
| Other Income/Exp. Net | $62 | $16 | -$3 | -$6 |
| Pre-Tax Income | $59 | $13 | -$7 | -$10 |
| Tax Expense | $11 | -$0 | $1 | $0 |
| Net Income | $48 | $13 | -$8 | -$10 |
| % Margin | – | – | -382.1% | – |
| EPS | 1.16 | 0.32 | -0.19 | -0.26 |
| % Growth | 262.5% | 268.4% | 26.9% | – |
| EPS Diluted | 1.13 | 0.31 | -0.19 | -0.26 |
| Weighted Avg Shares Out | 42 | 42 | 41 | 40 |
| Weighted Avg Shares Out Dil | 43 | 43 | 41 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $15 | $0 | -$19 |
| Interest Expense | $0 | $0 | $3 | -$15 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $59 | $13 | -$4 | -$10 |
| % Margin | – | – | -223.5% | – |